MCID: ADR016
MIFTS: 57

Adrenal Cortical Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Adrenal Cortical Carcinoma

MalaCards integrated aliases for Adrenal Cortical Carcinoma:

Name: Adrenal Cortical Carcinoma 42 12 13
Adrenocortical Carcinoma 42 12 77 54 30 6 45 15
Carcinoma of the Adrenal Cortex 12
Carcinoma Adrenocortical 56
Adrenal Cortex Carcinoma 17
Adrenocortical Cancer 56
Acc 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3948
MeSH 45 D018268
NCIt 51 C9325
SNOMED-CT 69 2227007
UMLS 74 C0206686

Summaries for Adrenal Cortical Carcinoma

NIH Rare Diseases : 54 Adrenocortical carcinoma is a rare cancer affecting the outside of the adrenal glands (adrenal cortex). These glands are on top of each kidney and are responsible for producing certain hormones and keeping blood pressure at normal levels. Adrenocortical carcinoma is relatively frequent in children compared to many other cancers, although the cancer may also affect adults. Girls are more often affected than boys. Symptoms of adrenocortical carcinoma may include pain in the abdomen, hypertension, weight gain, frequent urination and possibly deepening of the voice. These symptoms are due to the tumors causing excess secretion of hormones from the adrenal glands. Adrenocortical carcinoma may develop by chance alone, but at least 50% of the cancers are thought to be hereditary. There are a number of genes that have changes (mutations) that can cause an adrenocortical carcinoma, including TP53 and IGF2. There have been reports of both autosomal dominant inheritance and autosomal recessive inheritance. An adrenocortical carcinoma is diagnosed based on urine tests for abnormal levels of cortisol, the hormone released by the adrenal glands. Blood tests can also be conducted to measure levels of potassium and sodium in the blood. A CT scan or MRI may be used to search for a visible tumor in the adrenal cortex. Treatment options include surgical removal of the tumor, which is important to achieve a good long-term outlook. Chemotherapy, specifically a drug called mitotane, can be used to try to remove any remaining cancer after surgery. 

MalaCards based summary : Adrenal Cortical Carcinoma, also known as adrenocortical carcinoma, is related to adrenal carcinoma and adenoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Cortical Carcinoma is MIR195 (MicroRNA 195), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Corticotropin-releasing hormone signaling pathway. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and adrenal gland, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 77 Adrenocortical carcinoma (ACC) is an aggressive cancer originating in the cortex (steroid... more...

Related Diseases for Adrenal Cortical Carcinoma

Diseases related to Adrenal Cortical Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 adrenal carcinoma 31.0 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 IGF2
2 adenoma 30.2 CYP11B2 CYP21A2 HSD11B2 TP53
3 multiple endocrine neoplasia, type i 30.0 CHGA PRKAR1A SYP
4 acute adrenal insufficiency 30.0 CYP11A1 CYP21A2
5 small cell carcinoma 30.0 CHGA SYP TP53
6 luteoma 29.9 CYP21A2 STAR
7 papilloma of choroid plexus 29.8 IGF2 SYP TP53
8 gastrointestinal stromal tumor 29.5 CHGA IGF2 SYP TP53
9 polycystic ovary syndrome 29.3 CYP11A1 CYP17A1 CYP21A2 STAR
10 conn's syndrome 28.9 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2
11 lipoid congenital adrenal hyperplasia 28.3 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 MC2R
12 adrenal cortical adenoma 28.2 CYP11A1 CYP11B1 CYP17A1 CYP21A2 MC2R NR5A1
13 adrenocortical carcinoma, hereditary 25.7 CHGA CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
14 adrenocortical carcinoma with pure aldosterone hypersecretion 12.4
15 corpus callosum, agenesis of 11.9
16 aplasia cutis congenita 11.8
17 li-fraumeni syndrome 11.7
18 adenoid cystic carcinoma 11.7
19 agenesis of the corpus callosum with peripheral neuropathy 11.5
20 li-fraumeni syndrome 2 11.5
21 hereditary motor and sensory neuropathy with agenesis of the corpus callosum 11.4
22 corpus callosum, agenesis of, with abnormal genitalia 11.3
23 aplasia cutis congenita with intestinal lymphangiectasia 11.2
24 aplasia cutis congenita of limbs recessive 11.2
25 epidermolysis bullosa junctionalis with pyloric atresia 11.0
26 aicardi syndrome 11.0
27 acetyl-coa carboxylase deficiency 11.0
28 vici syndrome 11.0
29 corpus callosum, partial agenesis of, x-linked 11.0
30 adams-oliver syndrome 2 11.0
31 corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome 11.0
32 ceruminous adenocarcinoma 11.0
33 x-linked lissencephaly with abnormal genitalia 11.0
34 acinar cell carcinoma of pancreas 11.0
35 myocardial infarction 10.7
36 heart disease 10.7
37 esterase c 10.7
38 rere-related disorders 10.6
39 atrial fibrillation 10.6
40 arteries, anomalies of 10.5
41 heart valve disease 10.5
42 coronary artery anomaly 10.5
43 acute myocardial infarction 10.5
44 cardiac conduction defect 10.4
45 breast malignant phyllodes tumor 10.4 HSD11B2 TP53
46 fibroepithelial basal cell carcinoma 10.4 CHGA TP53
47 meninges sarcoma 10.4 IGF2 TP53
48 ischemic heart disease 10.4
49 hypertension, essential 10.4
50 insulinomatosis and diabetes mellitus 10.3 CHGA IGF2

Graphical network of the top 20 diseases related to Adrenal Cortical Carcinoma:



Diseases related to Adrenal Cortical Carcinoma

Symptoms & Phenotypes for Adrenal Cortical Carcinoma

UMLS symptoms related to Adrenal Cortical Carcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.8 CYP21A2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.8 CYP21A2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.8 NR5A1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.8 CYP11A1 CYP21A2 NR5A1 TP53
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.8 TP53
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.8 CYP11A1 CYP21A2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.8 CYP21A2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.8 CYP21A2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.8 CYP11A1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-62 9.8 TP53
11 Reduced mammosphere formation GR00396-S 9.17 CHGA CYP11B1 CYP21A2 HSD11B2 IGF2 MC2R

MGI Mouse Phenotypes related to Adrenal Cortical Carcinoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 CHGA CYP11A1 CYP11B1 CYP11B2 HSD11B2 IGF2
2 homeostasis/metabolism MP:0005376 10.22 CHGA CYP11A1 CYP11B1 CYP11B2 CYP17A1 HSD11B2
3 growth/size/body region MP:0005378 10.21 CHGA CYP11A1 CYP11B1 CYP11B2 CYP17A1 IGF2
4 endocrine/exocrine gland MP:0005379 10.2 CHGA CYP11A1 CYP11B1 CYP11B2 IGF2 INHA
5 behavior/neurological MP:0005386 10.19 CYP11A1 CYP11B1 CYP17A1 HSD11B2 IGF2 MC2R
6 mortality/aging MP:0010768 10.1 CHGA CYP11A1 CYP11B1 CYP17A1 HSD11B2 IGF2
7 liver/biliary system MP:0005370 9.85 CYP11A1 CYP11B2 IGF2 INHA PRKAR1A TP53
8 muscle MP:0005369 9.8 CHGA CYP11A1 CYP11B1 HSD11B2 IGF2 PRKAR1A
9 normal MP:0002873 9.7 CYP11A1 HSD11B2 INHA NR5A1 PRKAR1A SYP
10 renal/urinary system MP:0005367 9.43 CHGA CYP11B1 CYP11B2 HSD11B2 IGF2 TP53
11 reproductive system MP:0005389 9.32 CHGA CYP11A1 CYP11B2 CYP17A1 IGF2 INHA

Drugs & Therapeutics for Adrenal Cortical Carcinoma

Drugs for Adrenal Cortical Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
2
Racepinephrine Approved Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
3
Mecasermin Approved, Investigational Phase 3 68562-41-4
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
8
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
12
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
13
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
14
Etomidate Approved Phase 3,Phase 1,Phase 2 33125-97-2 667484 36339
15
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
16
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
21 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
22 Cola Phase 3,Phase 2,Phase 1,Early Phase 1
23 Epinephryl borate Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Respiratory System Agents Phase 3,Phase 2,Not Applicable
26 Adrenergic Agents Phase 3,Phase 2,Not Applicable
27 Bronchodilator Agents Phase 3,Phase 2,Not Applicable
28 Adrenergic alpha-Agonists Phase 3,Phase 2,Not Applicable
29 Vasoconstrictor Agents Phase 3,Phase 2,Not Applicable
30 Adrenergic Agonists Phase 3,Phase 2,Not Applicable
31 Autonomic Agents Phase 3,Phase 2,Not Applicable
32 Anti-Asthmatic Agents Phase 3,Phase 2,Not Applicable
33 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
34 Sympathomimetics Phase 3,Phase 2,Not Applicable
35 Mydriatics Phase 3,Phase 2,Not Applicable
36 Adrenergic beta-Agonists Phase 3,Phase 2,Not Applicable
37 Insulin, Globin Zinc Phase 3,Phase 2
38 insulin Phase 3,Phase 2
39 Mitogens Phase 3,Phase 2
40 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Hormonal Phase 3,Phase 2
42 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Etoposide phosphate Phase 3,Phase 2
45 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
46 Immunologic Factors Phase 3,Phase 2,Phase 1
47 Anesthetics, General Phase 3,Phase 1,Phase 2
48 Analgesics Phase 3
49 Adjuvants, Anesthesia Phase 3
50 Central Nervous System Depressants Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
6 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
7 Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
9 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
10 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3
11 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
12 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
15 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
16 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
17 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
18 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
19 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
20 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
21 Sunitinib in Refractory Adrenocortical Carcinoma Completed NCT00453895 Phase 2 Sunitinib
22 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
23 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
24 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
25 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
26 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
29 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
30 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
31 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
32 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
33 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
34 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
35 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
36 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
37 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
38 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
39 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
40 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
41 Cabozantinib in Advanced Adrenocortical Carcinoma Not yet recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
42 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
43 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Terminated NCT02720484 Phase 2 Nivolumab
44 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
45 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
47 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
48 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
49 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin
50 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide

Search NIH Clinical Center for Adrenal Cortical Carcinoma

Cochrane evidence based reviews: adrenocortical carcinoma

Genetic Tests for Adrenal Cortical Carcinoma

Genetic tests related to Adrenal Cortical Carcinoma:

# Genetic test Affiliating Genes
1 Adrenocortical Carcinoma 30

Anatomical Context for Adrenal Cortical Carcinoma

MalaCards organs/tissues related to Adrenal Cortical Carcinoma:

42
Cortex, Adrenal Cortex, Adrenal Gland, Liver, Kidney, Testes, Lung

Publications for Adrenal Cortical Carcinoma

Articles related to Adrenal Cortical Carcinoma:

(show top 50) (show all 1450)
# Title Authors Year
1
ADRENAL CORTICAL CARCINOMA IN INFANCY. ( 30726455 )
2019
2
Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature. ( 30963136 )
2019
3
Metastatic Adrenal Cortical Carcinoma Responding to Octreotide: A Case Report. ( 31073023 )
2019
4
Precocious pseudopuberty due to virilising adrenocortical carcinoma progressing to central precocious puberty after surgery. ( 30862670 )
2019
5
Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. ( 30936196 )
2019
6
Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature. ( 30477734 )
2019
7
Clinical and molecular prognostic factors in adrenocortical carcinoma. ( 30221891 )
2019
8
18F-FDG PET reveals an adrenocortical carcinoma in a bilateral adrenal multinodular disease. ( 30251165 )
2019
9
Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. ( 30315857 )
2019
10
In vitro antitumor activity of progesterone in human adrenocortical carcinoma. ( 30367443 )
2019
11
Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. ( 30443830 )
2019
12
Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails? ( 30469158 )
2019
13
Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma. ( 30476173 )
2019
14
Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. ( 30481155 )
2019
15
Case Report of an Adrenocortical Carcinoma Associated With Germline CHEK2 Mutation. ( 30623166 )
2019
16
Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature. ( 30721134 )
2019
17
Operative Management of Recurrent and Metastatic Adrenocortical Carcinoma: A Systematic Review. ( 30760340 )
2019
18
Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. ( 30770352 )
2019
19
Management of Adrenocortical Carcinoma. ( 30798468 )
2019
20
Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma. ( 30816525 )
2019
21
A case of metastatic adrenocortical carcinoma. ( 30863550 )
2019
22
Identification of four hub genes associated with adrenocortical carcinoma progression by WGCNA. ( 30886771 )
2019
23
Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: A systematic review of observational studies and meta-analysis. ( 30900615 )
2019
24
Label-free impedimetric immunosensor based on arginine-functionalized gold nanoparticles for detection of DHEAS, a biomarker of pediatric adrenocortical carcinoma. ( 30909017 )
2019
25
microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. ( 30918109 )
2019
26
Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. ( 30942448 )
2019
27
Adrenocortical carcinoma associated with giant bilateral myelolipomas in classic congenital adrenal hyperplasia. ( 30945697 )
2019
28
Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. ( 30970324 )
2019
29
Apoptosis regulation in adrenocortical carcinoma. ( 30978697 )
2019
30
Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. ( 30980285 )
2019
31
SIRT6 abrogation promotes adrenocortical carcinoma through activation of NF-κB signaling. ( 30989475 )
2019
32
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( 30991359 )
2019
33
Massive Migration of an Adrenocortical Carcinoma Thrombus. ( 31030537 )
2019
34
Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma. ( 31040822 )
2019
35
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. ( 31057613 )
2019
36
A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore. ( 31105294 )
2019
37
Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma. ( 28877067 )
2018
38
Co-culture of H295R Adrenocortical Carcinoma and BeWo Choriocarcinoma Cells to Study Feto-placental Interactions: Focus on Estrogen Biosynthesis. ( 29197012 )
2018
39
Adrenocortical Carcinoma Presenting as Reversible Dilated Cardiomyopathy. ( 30505399 )
2018
40
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma. ( 29192018 )
2018
41
Incidentally detected adrenocortical carcinoma in familial adenomatous polyposis: an unusual presentation of a hereditary cancer syndrome. ( 30181409 )
2018
42
Adrenocortical carcinoma characterized by gynecomastia: A case report. ( 29403152 )
2018
43
The coexistence of Cushing syndrome and gynecomastia as the manifestations of adrenocortical carcinoma. ( 30527206 )
2018
44
Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome. ( 28940135 )
2018
45
Synchronous adrenocortical carcinoma and ovarian malignant mixed germ cell tumor: A case report and literature review. ( 29768344 )
2018
46
RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. ( 30558313 )
2018
47
Adrenocortical carcinoma (ACC): When and why should we consider germline testing? ( 30104051 )
2018
48
Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database. ( 29982685 )
2018
49
A Rare Adrenal Incidentaloma That Mimics Adrenocortical Carcinoma. ( 29984033 )
2018
50
European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. ( 30042120 )
2018

Variations for Adrenal Cortical Carcinoma

Cosmic variations for Adrenal Cortical Carcinoma:

9 (show all 20)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.587G>T p.R196L 17:7674944-7674944 0
2 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.736A>G p.M246V 17:7674227-7674227 0
3 COSM326321 RB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.1994T>G p.L665R 13:48459721-48459721 0
4 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1960G>A p.V654M 13:48456349-48456349 0
5 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.617T>G p.L206R 19:14097604-14097604 0
6 COSM27887 GNAS adrenal gland,adrenal gland,adrenal cortical neoplasm,cortisol producing c.601C>T p.R201C 20:58909365-58909365 0
7 COSM27899 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.601C>A p.R201S 20:58909365-58909365 0
8 COSM27895 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.602G>A p.R201H 20:58909366-58909366 0
9 COSM4962873 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.679C>G p.Q227E 20:58909540-58909540 0
10 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 0
11 COSM5693 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.118A>G p.T40A 3:41224630-41224630 0
12 COSM5689 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>G p.S45C 3:41224646-41224646 0
13 COSM5678 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.107A>C p.H36P 3:41224619-41224619 0
14 COSM5667 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>T p.S45F 3:41224646-41224646 0
15 COSM5686 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.100G>A p.G34R 3:41224612-41224612 0
16 COSM5679 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.110C>G p.S37C 3:41224622-41224622 0
17 COSM17661 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.130C>G p.P44A 3:41224642-41224642 0
18 COSM5988492 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.101G>C p.G34A 3:41224613-41224613 0
19 COSM5681 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.95A>G p.D32G 3:41224607-41224607 0
20 COSM476 BRAF adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1799T>A p.V600E 7:140753336-140753336 0

Expression for Adrenal Cortical Carcinoma

Search GEO for disease gene expression data for Adrenal Cortical Carcinoma.

Pathways for Adrenal Cortical Carcinoma

GO Terms for Adrenal Cortical Carcinoma

Biological processes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.99 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2
2 male gonad development GO:0008584 9.73 INHA NR5A1 STAR
3 steroid metabolic process GO:0008202 9.72 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
4 cholesterol metabolic process GO:0008203 9.67 CYP11A1 CYP11B1 CYP11B2 STAR
5 cellular response to peptide hormone stimulus GO:0071375 9.58 CYP11A1 CYP11B1 CYP11B2
6 regulation of neuronal synaptic plasticity GO:0048168 9.57 STAR SYP
7 C21-steroid hormone biosynthetic process GO:0006700 9.56 CYP11A1 CYP11B1 CYP11B2 STAR
8 cellular response to potassium ion GO:0035865 9.55 CYP11B1 CYP11B2
9 regulation of steroid biosynthetic process GO:0050810 9.54 NR5A1 STAR
10 glucocorticoid metabolic process GO:0008211 9.52 HSD11B2 STAR
11 mineralocorticoid biosynthetic process GO:0006705 9.49 CYP11B2 CYP21A2
12 aldosterone biosynthetic process GO:0032342 9.48 CYP11B1 CYP11B2
13 cortisol biosynthetic process GO:0034651 9.46 CYP11B1 CYP11B2
14 sterol metabolic process GO:0016125 9.46 CYP11A1 CYP11B1 CYP11B2 CYP21A2
15 regulation of blood volume by renal aldosterone GO:0002017 9.43 CYP11B2 HSD11B2
16 steroid biosynthetic process GO:0006694 9.43 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 STAR
17 glucocorticoid biosynthetic process GO:0006704 9.1 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2

Molecular functions related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.85 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2 HSD11B2
2 heme binding GO:0020037 9.55 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
3 iron ion binding GO:0005506 9.35 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
4 corticosterone 18-monooxygenase activity GO:0047783 9.32 CYP11B1 CYP11B2
5 steroid 11-beta-monooxygenase activity GO:0004507 9.26 CYP11B1 CYP11B2
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.02 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2

Sources for Adrenal Cortical Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....